Effects for glucose metabolism, body composition, and circulatory dynamics of SGLT2 inhibitor
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2018
Price : $35 *
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 06 Aug 2018 Status changed to discontinued.
- 20 Feb 2018 New trial record
- 01 Feb 2018 Results published in the Diabetes Therapy.